Intermountain Heart Institute at Intermountain Medical Center

(801) 507-4701Map5121 S. Cottonwood StreetMurray, UT 84107
Intermountain Heart Institute logo
Heart Valve & Structural Heart Disease Program
Questions & Referrals:
(801) 507-4795

Video

Install Flash Player to View this Video

The methods we use to treat heart valve and structural heart disease are quickly advancing. The clinical trials listed below help us evaluate new therapies and devices for patients like you.

To learn more, please contact us at 801-507-4795.

Aortic Stenosis

Trial: Partner II Trial
Long Title: Placement of Aortic Transcatheter Valves Trial
Principal Investigators: Brian Whisenant, MD and Kent Jones, MD
Sponsor: Edwards Lifesciences, LLC
Description: The purpose of the PARTNER II trial is to determine the safety and effectiveness of the Edwards SAPIEN XT device and NovaFlex delivery systems in inoperable patients with symptomatic critical aortic valve stenosis. Patients with critical aortic stenosis who are characterized as high risk for surgery or inoperable may be eligible for this study. The investigational replacement heart valve is compressed on a balloon and delivered to the heart via a catheter inserted into either the femoral artery in the leg (transfemoral) or a small incision between the ribs (transapical). This study is comparing the SAPIEN XT device to the original SAPIEN device used in the PARTNER I trial.

View PARTNER videos (top right) to see animations of less invasive transfemoral and transapical aortic valve implantation.

Trial: SURTAVI
Long Title: Safety and Efficacy Study of the Medtronic CoreValve System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement
Principal Investigator: Brian Whisenant, MD
Sponsor: Medtronic
Description: The SURTAVI trial is a randomized clinical trial comparing the Medtronic CoreValve® System with surgical aortic valve replacement. The trial is for patients with severe aortic valve stenosis who are at intermediate risk to undergo open-heart surgery. The trial will evaluate the potential for the minimally-invasive CoreValve System to be considered for less-sick patients who typically are treated with open-heart surgical aortic valve replacement today.

Mitral Regurgitation

Trial: COAPT
Long Title: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation
Principal Investigator: Brian Whisenant, MD
Sponsor: Evalve (a wholly owned subsidiary of Abbott Vascular)
Description: The COAPT Trial is designed to study the safety and effectiveness of the MitraClip® device in patients who have symptomatic heart failure and significant functional mitral regurgitation but who are considered not appropriate for surgery. The MitraClip device is placed via a catheter from the femoral vein and does not require a chest incision, use of a heart-lung machine, or stopping of the heart.

Copyright © , Intermountain Healthcare, All rights reserved.